In the same study the authors evaluated the methylation profiles of MAPT promoter in the frontal cortex and hippocampus of controls, Alzheimer's disease patients, PD patients, and subjects with other tauopathies and synucleinopathies. This evidence concerns the gene MAPT and Parkinson disease.